JPWO2020168337A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020168337A5 JPWO2020168337A5 JP2021548233A JP2021548233A JPWO2020168337A5 JP WO2020168337 A5 JPWO2020168337 A5 JP WO2020168337A5 JP 2021548233 A JP2021548233 A JP 2021548233A JP 2021548233 A JP2021548233 A JP 2021548233A JP WO2020168337 A5 JPWO2020168337 A5 JP WO2020168337A5
- Authority
- JP
- Japan
- Prior art keywords
- nri
- pharmaceutical composition
- maoi
- dosage form
- phenelzine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 56
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 56
- 239000008194 pharmaceutical composition Substances 0.000 claims 47
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 45
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 45
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims 17
- 239000002552 dosage form Substances 0.000 claims 17
- 229960000964 phenelzine Drugs 0.000 claims 17
- 238000013270 controlled release Methods 0.000 claims 14
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 10
- 229960003914 desipramine Drugs 0.000 claims 10
- 229960002430 atomoxetine Drugs 0.000 claims 9
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims 9
- 229960002601 protriptyline Drugs 0.000 claims 8
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims 8
- 208000020016 psychiatric disease Diseases 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 6
- 229960001104 droxidopa Drugs 0.000 claims 4
- QXWYKJLNLSIPIN-SFYZADRCSA-N droxidopa Chemical compound OC(=O)[C@H](N)[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-SFYZADRCSA-N 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 229960002672 isocarboxazid Drugs 0.000 claims 1
- 229960002813 lofepramine Drugs 0.000 claims 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 229960004644 moclobemide Drugs 0.000 claims 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims 1
- 229950004211 nisoxetine Drugs 0.000 claims 1
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 claims 1
- 229960000245 rasagiline Drugs 0.000 claims 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 claims 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 1
- 229960003770 reboxetine Drugs 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 229960003732 tyramine Drugs 0.000 claims 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806831P | 2019-02-17 | 2019-02-17 | |
| US62/806,831 | 2019-02-17 | ||
| PCT/US2020/018567 WO2020168337A1 (en) | 2019-02-17 | 2020-02-18 | Compositions and methods for treatment of depression and other disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521208A JP2022521208A (ja) | 2022-04-06 |
| JP2022521208A5 JP2022521208A5 (https=) | 2023-03-01 |
| JPWO2020168337A5 true JPWO2020168337A5 (https=) | 2023-03-01 |
Family
ID=72045151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548233A Pending JP2022521208A (ja) | 2019-02-17 | 2020-02-18 | うつ病及び他の障害の治療のための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12465611B2 (https=) |
| EP (1) | EP3923919A4 (https=) |
| JP (1) | JP2022521208A (https=) |
| CN (1) | CN113631157A (https=) |
| AU (2) | AU2020223284A1 (https=) |
| CA (1) | CA3130580A1 (https=) |
| WO (1) | WO2020168337A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4727545A2 (en) * | 2023-06-16 | 2026-04-22 | Neurawell Therapeutics | Combination treatments for depression and other disorders |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4999382A (en) | 1988-10-26 | 1991-03-12 | Massachusetts Institute Of Technology | Compositions for treating tobacco withdrawal symptoms and methods for their use |
| US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
| US20040102440A1 (en) | 2002-07-01 | 2004-05-27 | Wong Erik Ho Fong | Method of promoting smoking cessation |
| WO2005072705A1 (en) | 2004-01-29 | 2005-08-11 | Neuromolecular, Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions |
| WO2005102366A2 (en) | 2004-04-19 | 2005-11-03 | Philip Maxwell Satow | Lithium combinations, and uses related thereto |
| US20090054489A1 (en) | 2005-02-23 | 2009-02-26 | Prexa Pharmaceuticals, Inc. | Multimediator Dopamine Transport Inhibitors, and Uses Related Thereto |
| CA2598838A1 (en) | 2005-02-23 | 2006-08-31 | Prexa Pharmaceuticals, Inc. | Multimediator 5-ht6 receptor antagonists, and uses related thereto |
| EP2258382A3 (en) | 2005-03-31 | 2014-05-14 | Amylin Pharmaceuticals, LLC | Amylin and amylin agonists for treating psychiatric diseases and disorders |
| CN101203505A (zh) | 2005-04-22 | 2008-06-18 | 惠氏公司 | 苯并二氢吡喃和苯并吡喃衍生物及其用途 |
| MX2007012882A (es) | 2005-04-22 | 2007-12-10 | Wyeth Corp | Nuevas combinaciones terapeuticas para el tratamiento o prevencion de la depresion. |
| KR20080105104A (ko) * | 2006-03-24 | 2008-12-03 | 와이어쓰 | 우울증 치료를 위한 신규한 치료학적 병용제 |
| CA2648280C (en) | 2006-04-03 | 2014-03-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
| CN101657193A (zh) * | 2007-03-09 | 2010-02-24 | 切尔西治疗公司 | 用于治疗纤维肌痛的屈昔多巴及其药物组合物 |
| EP2514417A3 (en) * | 2007-05-07 | 2013-01-30 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
| WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
| WO2011057199A1 (en) | 2009-11-06 | 2011-05-12 | Adenios, Inc. | Compositions for treating cns disorders |
| GB201003734D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
| GB201003731D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
| WO2011119227A2 (en) | 2010-03-25 | 2011-09-29 | Columbia Northwest Pharmaceuticals, Llc | Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients |
| PL2560624T3 (pl) * | 2010-04-23 | 2019-01-31 | Kempharm, Inc. | Formulacja terapeutyczna do zmniejszania skutków ubocznych leku |
| US20130324609A1 (en) | 2010-10-08 | 2013-12-05 | University Of Utah Research Foundation | Depression disorder therapeutics with creatine analogs |
| US20130217673A1 (en) | 2012-02-22 | 2013-08-22 | Warsaw Orthopedic, Inc | Mixed monoamine reuptake inhibitor in a biodegradable polymer carrier |
| PE20141906A1 (es) * | 2012-03-12 | 2014-12-05 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento |
| WO2014120936A2 (en) | 2013-01-30 | 2014-08-07 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
| US10828302B2 (en) | 2016-03-10 | 2020-11-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
| US10624939B2 (en) | 2017-05-23 | 2020-04-21 | Luke Klele | Natural product compositions for treating or managing symptoms of ADD, ADHD, anxiety, and depression |
| US20180338959A1 (en) | 2017-05-24 | 2018-11-29 | Ovid Therapeutics Inc. | Treatment of depressive disorders |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| CN111233737B (zh) | 2020-03-16 | 2021-05-11 | 东莞市东阳光新药研发有限公司 | 芳杂环类衍生物的盐及其用途 |
-
2020
- 2020-02-18 WO PCT/US2020/018567 patent/WO2020168337A1/en not_active Ceased
- 2020-02-18 AU AU2020223284A patent/AU2020223284A1/en not_active Abandoned
- 2020-02-18 CN CN202080024259.3A patent/CN113631157A/zh active Pending
- 2020-02-18 US US17/431,422 patent/US12465611B2/en active Active
- 2020-02-18 CA CA3130580A patent/CA3130580A1/en active Pending
- 2020-02-18 JP JP2021548233A patent/JP2022521208A/ja active Pending
- 2020-02-18 EP EP20756497.2A patent/EP3923919A4/en not_active Withdrawn
-
2023
- 2023-09-05 AU AU2023226657A patent/AU2023226657A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| HU225534B1 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| SK14612003A3 (sk) | Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu | |
| CA2453263A1 (en) | Pharmaceutical compositions containing terbinafine and use thereof | |
| JP2020522560A5 (https=) | ||
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| JP2013536837A5 (https=) | ||
| CZ291941B6 (cs) | Farmaceutické kombinace obsahující tramadol | |
| CN104379138B (zh) | 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 | |
| JP2016505050A5 (https=) | ||
| EP1896076A2 (en) | Compositions and methods for enhancement of sexual function | |
| JPWO2020070706A5 (https=) | ||
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| JPWO2020168337A5 (https=) | ||
| JP2021530568A5 (https=) | ||
| TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
| JPWO2022107125A5 (https=) | ||
| JP7312286B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
| EP3999051B1 (en) | Inhalation dosage forms of glycerol tribenzoate and/or glycerol dibenzoate for use in the treatment of huntington's disease | |
| JP2007513095A5 (https=) | ||
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| JPWO2020018291A5 (https=) | ||
| HK40075156B (en) | Inhalation dosage forms of glycerol tribenzoate and/or glycerol dibenzoate for use in the treatment of huntington's disease |